Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Mixed lineage kinase 3 contributes to myocardial ischemia/reperfusion injury by regulating neutrophil activation.Basic research in cardiology · 2025
   Article
2. Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2024
   Review
3. Impact of C-reactive protein levels and role of anakinra in patients with ST-elevation myocardial infarction.International journal of cardiology · 2024
   Article
4. Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients.Translational medicine @ UniSa · 2024
   Review
5. Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets.Journal of clinical medicine · 2023
   Review
6. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches.JACC. Basic to translational science · 2021
   Article
7. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.Immunity · 2019
   Review
8. The NLRP3 inflammasome in acute myocardial infarction.Nature reviews. Cardiology · 2018
   Review
9. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.Journal of the American College of Cardiology · 2017
   Review
10. The IL-1RI Co-Receptor TILRR (JACC. Basic to translational science · 2017
    Article
11. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.Circulation research · 2016
    Review
12. Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.Molecular medicine (Cambridge, Mass.) · 2015
    Article
13. Targeting interleukin-1 in heart failure and inflammatory heart disease.Current heart failure reports · 2015
    Review

Corrections and comments

• Comment on
  The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.2015

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as